BridgeBio's Attruby challenges Pfizer's Vyndamax legacy in pivotal ATTR trial

BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial

Pharmaceutical Technology

An indirect comparison highlights the potential of BridgeBio's Attruby to best Pfizer's tafamidis in frontline ATTR-CM.

pharminent May 12, 2026 (Last updated: May 16, 2026)

Pharmaceutical Technology

An indirect comparison highlights the potential of BridgeBio’s Attruby to best Pfizer’s tafamidis in frontline ATTR-CM.

Related Stories